Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors

NCT07293754 is registered in ClinicalTrials.gov with Repertoire Immune Medicines as lead sponsor.

NCT NCT07293754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07293754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
Lead sponsor
Repertoire Immune Medicines
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 12, 2025
Completion date
April 15, 2029
Enrollment
150 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumor